Clinical Trials Sponsored by LaNova Medicines Limited

Total 146 results

LaNova Medicines Limited

Withdrawn

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Relapsed or Refractory Multiple Myeloma | Other Plasma Cell Diseases
LaNova Medicines Limited

Terminated

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Advanced Solid Tumor

United States
LaNova Medicines Limited

Terminated

Study of LM-061 in Subjects in Advanced Tumors

Advanced Tumours

Australia
LaNova Medicines Limited

Suspended

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

Malignant Tumors

China
LaNova Medicines Limited

Terminated

A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours

Advanced Tumours

China
LaNova Medicines Limited

Recruiting

A Study of LM-24C5 For Advanced Solid Tumors

Advanced Solid Tumor

United States
LaNova Medicines Limited

Recruiting

Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Advanced Solid Tumor

China
LaNova Medicines Limited

Terminated

Study of LM-102 in Subjects in Advanced Tumors

Advanced Solid Tumors

United States
LaNova Australia Pty Limited

Terminated

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumor

Australia
LaNova Australia Pty Limited

Recruiting

Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours

Advanced Solid Tumor

Australia
LaNova Medicines Zhejiang Co., Ltd.

Not yet recruiting

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
LaNova Medicines Zhejiang Co., Ltd.

Active, not recruiting

Study of LM-302 in Patients With Advance Solid Tumors

Advanced Solid Tumor

China
LaNova Medicines Zhejiang Co., Ltd.

Recruiting

A LM-302 Combined With Toripalimab Phase II Study

Gastric Cancer | Pancreatic Cancer

China
LivaNova
OPEN VIE Limited

Suspended

IMPACT of AspireSR® for VNS Therapy on Healthcare Resource Utilisation and Clinical Outcomes. (IMPACT)

Epilepsy

United Kingdom
LivaNova
OPEN VIE Limited

Active, not recruiting

Non-interventional Study Describing Healthcare Resource Utilisation and Clinical Outcomes Associated With VNS Therapy in UK. (DANTE)

Epilepsy

United Kingdom
Nova Laboratories Limited

Completed

Pharmacokinetics of Oral Hydroxyurea Solution (HUPK)

Sickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, Thalassemia

United Kingdom, Jamaica
Nova Laboratories Limited

Completed

Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions

Acute Lymphoblastic Leukemia

South Africa
Nova Laboratories Limited

Completed

Oral Liquid 13-cis-retinoic Acid (13-CRA) (My-CRA)

Neuroblastoma

United Kingdom
Hua Medicine Limited

Completed

DDI Study Between Dorzagliatin and Rifampicin

Drug Interaction

China
Hua Medicine Limited

Completed

Human Mass Balance Study of HMS5552 in Healthy Subjects

Healthy Subject

United States
Hua Medicine Limited

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus
Hua Medicine Limited

Completed

Drug Interaction Study Between Dorzagliatin and Sitagliptin

Patients

United States
Hua Medicine Limited

Completed

A Clinical Study to Access the Pharmacokinetics of HMS5552 in Hepatic Impaired Subjects and Healthy Volunteers

Type 2 Diabetes Mellitus

China
Hua Medicine Limited

Completed

Drug Interaction Study Between Dorzagliatin and Empagliflozin

Patients

United States
Hua Medicine Limited

Completed

DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin

Drug Interaction

China
Hua Medicine Limited

Completed

A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers

Type II Diabetes Mellitus

China
Hua Medicine Limited

Completed

Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM

Type 2 Diabetes Mellitus

United States
Hua Medicine Limited

Completed

Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients

Type 2 Diabetes

China
Citrine Medicine Limited

Completed

A Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of EDS in Patients With OSA

Excessive Daytime Sleepiness

China
Hua Medicine Limited

Completed

A Clinical Study to Access the Pharmacokinetics of HMS5552 in Renal Impaired Subjects and Healthy Volunteers

Type 2 Diabetes Mellitus

China
George Medicines PTY Limited

Completed

Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension (GMRx2_PCT)

Hypertension

Australia, United States, Nigeria, Sri Lanka, United Kingdom
George Medicines PTY Limited

Completed

Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension (GMRx2_ACT)

Hypertension

Australia, United States, United Kingdom, Poland, Sri Lanka, New Zealand, Czechia
Everstar Medicines (Shanghai) Limited

Completed

A Study of Ralinepag in Healthy Chinese Adult Subjects

Healthy Volunteer | Pharmacokinetic Study

China
Hua Medicine Limited
Covance

Completed

Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects

Diabetes Mellitus, Type 2

China
LaNova Medicines Development Co., Ltd.
Shanghai Zhongshan Hospital; First Affiliated Hospital of Zhejiang University; Sir Run Run Shaw Hospital and other collaborators

Terminated

Study of LM-102 in Patients With Advance Solid Tumors

Advanced Solid Tumor

China
InSilico Medicine Hong Kong Limited

Completed

A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects

Idiopathic Pulmonary Fibrosis

New Zealand
University Medicine Greifswald
SDI Limited

Completed

Fluoride Therapies on Hypersensitive Carious Lesions in Primary Teeth

Dentin Hypersensitivity | Active Dental Caries

Germany
Nova Immunotherapeutics Limited
The Emmes Company, LLC; Nova Laboratories Limited; Mercia Pharma Inc.

Unknown

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101) (MER4101)

Influenza, Human

United States
InSilico Medicine Hong Kong Limited

Recruiting

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)

United States
InSilico Medicine Hong Kong Limited

Recruiting

Study Evaluating ISM5411 Administered Orally to Healthy Volunteers

Healthy Subjects

Australia
InSilico Medicine Hong Kong Limited

Recruiting

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis (IPF)

China
ATXA Therapeutics Limited
Hammersmith Medicines Research

Recruiting

Safety, Pharmacokinetics (PK) and Relative Bioavailability of NTP42:KVA4 as a Solid Oral Dose

Healthy

United Kingdom
ATXA Therapeutics Limited
Hammersmith Medicines Research

Completed

Safety, Tolerability and Pharmacokinetics of NTP42:KVA4

Healthy

United Kingdom
Collaborative Medicinal Development Pty Limited

Active, not recruiting

ALS Treatment Extension Study

Amyotrophic Lateral Sclerosis

Australia
Collaborative Medicinal Development Pty Limited

Completed

Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease

Parkinson Disease

Australia
Collaborative Medicinal Development Pty Limited

Completed

Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors

Neoplasms

Australia
Collaborative Medicinal Development Pty Limited

Unknown

CuATSM Compared With Placebo for Treatment of ALS/MND

Amyotrophic Lateral Sclerosis

Australia
Collaborative Medicinal Development Pty Limited

Completed

Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001

Amyotrophic Lateral Sclerosis

Australia
Collaborative Medicinal Development Pty Limited

Completed

Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND

Motor Neuron Disease | Amyotrophic Lateral Sclerosis

Australia
Medicines for Malaria Venture
Richmond Pharmacology Limited

Completed

Healthy Volunteer Study of the Pharmacokinetics of Oral Piperaquine With OZ439 + TPGS Formulation in the Fasted State

Malaria

United Kingdom

Clinical Trials Sponsored by LaNova Medicines Limited

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations